AIP
HRTX icon

Ameritas Investment Partners’s Heron Therapeutics HRTX Stock Holding History

Ameritas Investment Partners’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.5K Hold
15,618
– – ﹤0.01% 2793
2025
Q4 		$20.3K Hold
15,618
– – ﹤0.01% 2633
2025
Q3 		$19.7K Hold
15,618
– – ﹤0.01% 2666
2025
Q2 		$32.3K Buy
15,618
+4,116
+36% +$8.4K ﹤0.01% 2451
2025
Q1 		$25.3K Hold
11,502
– – ﹤0.01% 2447
2024
Q4 		$17.6K Hold
11,502
– – ﹤0.01% 2686
2024
Q3 		$22.9K Hold
11,502
– – ﹤0.01% 2581
2024
Q2 		$40.3K Buy
11,502
+4,374
+61% +$13.4K ﹤0.01% 2259
2024
Q1 		$19.7K Hold
7,128
– – ﹤0.01% 2568
2023
Q4 		$12.1K Hold
7,128
– – ﹤0.01% 2780
2023
Q3 		$7.34K Hold
7,128
– – ﹤0.01% 2917
2023
Q2 		$8.27K Hold
7,128
– – ﹤0.01% 2955
2023
Q1 		$10.8K Hold
7,128
– – ﹤0.01% 2708
2022
Q4 		$20.2K Hold
7,128
– – ﹤0.01% 2561
2022
Q3 		$30K Hold
7,128
– – ﹤0.01% 2303
2022
Q2 		$19K Hold
7,128
– – ﹤0.01% 2563
2022
Q1 		$41K Hold
7,128
– – ﹤0.01% 2171
2021
Q4 		$65K Hold
7,128
– – ﹤0.01% 1969
2021
Q3 		$76K Hold
7,128
– – ﹤0.01% 1859
2021
Q2 		$111K Hold
7,128
– – ﹤0.01% 1663
2021
Q1 		$116K Sell
7,128
-613
-8% -$10.9K ﹤0.01% 1570
2020
Q4 		$164K Hold
7,741
– – 0.01% 1263
2020
Q3 		$115K Hold
7,741
– – 0.01% 1348
2020
Q2 		$114K Buy
7,741
+516
+7% +$8.48K 0.01% 1332
2020
Q1 		$85K Hold
7,225
– – ﹤0.01% 1364
2019
Q4 		$170K Buy
7,225
+940
+15% +$20.8K 0.01% 1191
2019
Q3 		$116K Hold
6,285
– – 0.01% 1376
2019
Q2 		$117K Buy
6,285
+614
+11% +$12.3K 0.01% 1406
2019
Q1 		$139K Hold
5,671
– – 0.01% 1260
2018
Q4 		$147K Hold
5,671
– – 0.01% 1135
2018
Q3 		$179K Buy
5,671
+352
+7% +$13.1K 0.01% 1157
2018
Q2 		$207K Buy
5,319
+734
+16% +$23.4K 0.01% 1050
2018
Q1 		$127K Buy
4,585
+1,041
+29% +$23.6K 0.01% 1337
2017
Q4 		$64K Hold
3,544
– – ﹤0.01% 1770
2017
Q3 		$58K Hold
3,544
– – ﹤0.01% 1791
2017
Q2 		$49K Hold
3,544
– – ﹤0.01% 1916
2017
Q1 		$53K Buy
+3,544
New +$49.1K ﹤0.01% 1801

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Ameritas Investment Partners's HRTX Position: Q1 2026 in Review

Ameritas Investment Partners held its Heron Therapeutics (HRTX) position steady in Q1 2026 at 15,618 shares worth $12.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2793.

Ameritas Investment Partners first reported a position in HRTX in Q1 2017 and has held it in 37 quarters since. The position peaked at $207K in Q2 2018. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Ameritas Investment Partners held 15,618 shares of Heron Therapeutics worth $12.5K as of Q1 2026.
  • Ameritas Investment Partners left its Heron Therapeutics share count unchanged in Q1 2026.
  • Heron Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2793 holding.
  • Ameritas Investment Partners first reported a position in Heron Therapeutics in Q1 2017 and has held it in 37 quarters since.
  • Ameritas Investment Partners's Heron Therapeutics position peaked at $207K in Q2 2018.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.